兴齐眼药: 前次募集资金使用情况鉴证报告

Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Shenyang Xingqi Eye Pharmaceutical Co., Ltd. as of December 31, 2024, highlighting the financial figures and project statuses [1][2][3]. Fundraising Overview - The company raised a total of RMB 599,669,492.10 through the issuance of 5,763,282 shares, with actual funds received amounting to RMB 581,870,425.73 after deducting underwriting fees [1][2]. - The funds were fully received by December 22, 2021, and verified by a certified public accountant [1]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 382,520,531.09, with remaining funds of RMB 195,077,792.24 held in a dedicated bank account [2][3]. - The company has not changed the investment projects but adjusted the implementation locations for certain projects, specifically the "R&D Center Construction" project [2][3]. Project Status and Economic Benefits - The "Single-Dose Production Line Construction" project is expected to achieve an internal rate of return of 51.96% and a net present value of RMB 904,582,400, with an anticipated annual revenue of RMB 1,970,283,200 once operational [4]. - The "R&D Center Construction and New Drug Development" project aims to enhance the company's R&D capabilities, although direct economic benefits cannot be quantified at this stage due to the nature of drug development processes [4]. Financial Summary - The total amount of funds raised was RMB 599,669,492.10, with cumulative usage amounting to RMB 399,868,000, indicating a significant portion of the funds has been allocated to various projects [3][4]. - The company has approved the permanent allocation of surplus funds to supplement working capital, reflecting a strategic financial management approach [2][3].